

QUE LIPPO HEALTHCARE LIMITED

(Company Registration No. 201304341E)
(Incorporated in the Republic of Singapore)
(the “**Company**”)

(In receivership over charged shares in certain subsidiaries)

NOTICE OF EXTRAORDINARY GENERAL MEETING

All capitalised terms used in this Notice which are not defined herein shall, unless the context otherwise requires, have the same meaning ascribed to them in the circular to Shareholders dated 26 September 2018.

NOTICE IS HEREBY GIVEN that an Extraordinary General Meeting of the Company will be held at Stephen Riady Auditorium@NTUC, Level 7, NTUC Centre, One Marina Boulevard, Singapore 018989 on 11 October 2018 at 10 a.m., for the purpose of considering and, if thought fit, passing with or without modifications, the following resolutions:

Shareholders should note that Resolution 1 and Resolution 2 are inter-conditional upon each other. Accordingly, in the event that any of these resolutions is not approved, the other resolution will not be duly passed.

ORDINARY RESOLUTIONS

RESOLUTION 1 – THE PROPOSED ACQUISITION OF 40% OF THE TOTAL ISSUED SHARE CAPITAL OF BOWSPRIT CAPITAL CORPORATION LIMITED

That, subject to and contingent upon the passing of Resolution 2, for the purposes of Chapters 9 and 10 of the Catalist Rules Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited (the “**Catalist Rules**”):

- (a) approval be and is hereby given for the acquisition by the Company of 400,000 ordinary shares, representing 40% of the total issued share capital of Bowsprit Capital Corporation Limited, held by LK REIT Management Pte. Ltd. (“**LKRM**”), upon the terms and conditions of the conditional sale and purchase agreement dated 18 September 2018 entered into by the Company and OUE Limited as purchasers, LKRM as vendor and PT Lippo Karawaci Tbk (“**PT LK**”) as guarantor (the “**Manager CSPA**”) (the “**Proposed Manager Acquisition**”); and
- (b) the directors of the Company (the “**Directors**”) and each of them be and are hereby authorised to complete and to do all acts and things (including, without limitation, executing all such documents as may be required) as they or he may consider necessary, desirable or expedient for the purposes of or in connection with and to give effect to this resolution (including any amendment to the Manager CSPA, execution of any other agreements or documents and procurement of third party consents).

Note to Resolution 1:

- (1) Pursuant to Rule 919 of the Catalist Rules, Dr. Stephen Riady and his associates will abstain from exercising any voting rights in relation to Resolution 1.

RESOLUTION 2 – THE PROPOSED ACQUISITION OF 83,593,683 UNITS OF FIRST REAL ESTATE INVESTMENT TRUST

That, subject to and contingent upon the passing of Resolution 1, for the purposes of Chapters 9 and 10 of the Catalist Rules:

- (a) approval be and is hereby given for the acquisition by OLH Healthcare Investments Pte. Ltd. (the “**OHI**”) of 83,593,683 units, representing approximately 10.63% of the total issued units of First Real Estate Investment Trust, held by Bridgewater International Limited (“**Bridgewater**”), upon the terms and conditions of the conditional sale and purchase agreement dated 18 September 2018 entered into by OHI as purchaser, Bridgewater as vendor and PT LK as guarantor (the “**Units CSPA**”) (the “**Proposed Units Acquisition**”); and
- (b) the directors of the Company (the “**Directors**”) and each of them be and are hereby authorised to complete and to do all acts and things (including, without limitation, executing all such documents as may be required) as they or he may consider necessary, desirable or expedient for the purposes of or in connection with and to give effect to this resolution (including any amendment to the Units CSPA, execution of any other agreements or documents and procurement of third party consents).

Note to Resolution 2:

- (1) Pursuant to Rule 919 of the Catalist Rules, Dr. Stephen Riady and his associates will abstain from exercising any voting rights in relation to Resolution 2.

BY ORDER OF THE BOARD

Ng Ngai
Company Secretary
26 September 2018

Personal data privacy

By submitting an instrument appointing a proxy(ies) and/or representative(s) to attend, speak and vote at the Extraordinary General Meeting and/or any adjournment thereof, a member of the Company (i) consents to the collection, use and disclosure of the member’s personal data by the Company (or its agents or service providers) for the purpose of the processing, administration and analysis by the Company (or its agents or its service providers) of proxies and representatives appointed for the Extraordinary General Meeting (including any adjournment thereof) and the preparation and compilation of the attendance lists, minutes and other documents relating to the Extraordinary General Meeting (including any adjournment thereof), and in order for the Company (or its agents or service providers) to comply with any applicable laws, listing rules, take-over rules, regulations and/or guidelines (collectively, the “**Purposes**”), (ii) warrants that where the member discloses the personal data of the member’s proxy(ies) and/or representative(s) to the Company (or its agents or service providers), the member has obtained the prior consent of such proxy(ies) and/or representative(s) for the collection, use and disclosure by the Company (or its agents or service providers) of the personal data of such proxy(ies) and/or representative(s) for the Purposes, and (iii) agrees that the member will indemnify the Company in respect of any penalties, liabilities, claims, demands, losses and damages as a result of the member’s breach of warranty.